Download our brochure

Trusted CRDO & CDMO

Active Pharmaceutical Ingredients
Custom Intermediates
Lipid & Polymer Excipients

Join SEQENS April, 25-27, 2023 at


Pennsylvania Convention Center Philadelphia, PA

Come visit us at booth #441

Download our Custom R&D and Custom Development and Manufacturing capability brochure and request a meeting.


François Macarez

Head of Marketing & Business Development

Cameron Faghani

Director, Sales & Business Development

Henry Shelley

Sales Director, Generic API’s, North America


Highly Potent Active Pharmaceutical Ingredients (HPAPIs)

Shifting needs are driving a stronger demand to manufacture Highly Potent Active Pharmaceutical Ingredients (HPAPIs). In addition to its HPAPI R&D and industrial capacities available at 4 production sites, Seqens has invested $29M supported by the French government in a new workshop suitable for the manufacturing of OEB4 API in its Aramon site (France). Seqens has HPAPI expertise based on years of experience.

This new workshop adds a total capacity of production of 10-20 MT/year of product and/or intermediates

Safety and Efficiency:
New workshop production unit with containment adapted for OEB4 molecules (<1µg/m3) in each step with Energy consumption optimized with thermal regulation with skid and re-use of fatal energy.

Lipids & Polymers Expertise

Seqens is strongly committed to the potential of new cutting-edge technologies for lipids, especially in the U.S. We have more than 10 years’ of experience of developing cationic / ionizable lipides for RNA encapsulation and in developing and batch delivering – taking clients from pre-clinical to commercialization.

  • We can help at every step along the way by offering multi-steps synthesis and purification (chromatography) and end concentration and packaging in ISO7 GMP-suite
  • Capacity exceeds 10 kg / batch, with approx. 100 kg total capacity
  • We help sponsors with RSM back-integration and derisking
  • We provide full analytics (incl. HPLC-CAD) for impurity determination, methods dvpt & validation, and stability studies

Contract Research & Development Services

Seqens has created a new line of services – a CRDO (Contract Research & Development Organization) to complement our CDMO services.

Focused on drug substance small molecules, our CRDO services offers state-of-the-art capabilities and additional capacity of our Boston’Lab R&D Center, capable of taking sponsors from the discovery phase of product development to the scale up of New Chemical Entities for clinical supply thanks to a team of over 30 R&D professionals (3/4s have Ph.D.’s), all with deep experience in small molecule development. We offer a range of CRDO services, including:

  • Process Research – Custom synthesis from g – kg for API’s or intermediates
  • Process Development – Custom synthesis from kg – metric tons
  • cGMP manufacturing of pharmaceutical actives and intermediates for clinical trials
  • Route scouting
  • Production of non-GMP quantities for in-vitro testing and tox studies